Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
BREAKING: USD extends gains to 1% after the FOMC Conference
BREAKING: EURUSD down 0.4% after the FOMC!
Daily Summary: Will the Fed shake the market?
Warsh to bring back lower rates?